WHO says the antibacterial pipeline reveals a dual crisis: scarcity and lack of innovation

Taking stock of the drug industry, from the lab to the medicine chest

October 2, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Melissa Brower/Centers for Disease Control and Prevention via AP STAT+ | WHO says the antibacterial pipeline reveals a dual crisis: scarcity and lack of innovation Antimicrobial resistance is one of the most urgent global health threats, causing over one million deaths annually By Ed Silverman STAT+ | Amgen says its cholesterol shot prevented heart problems in a broad population The results of the trial of Repatha in a 12,000-patient study could help the drug reach a large market, analysts say. By Matthew Herper STAT+ | The biotech scorecard for the fourth quarter: 36 stock-moving events to watch Here's a look at top trial readouts and FDA drug approval decisions for Summit Therapeutics, BridgeBio, and other biotech companies. By Adam Feuerstein Adobe STAT+ | Fights over Tylenol, SSRIs highlight the enduring lack of pregnant women in drug trials Shutting pregnant women out of clinical trials to protect them and their babies has had the opposite effect, experts say. By Lizzy Lawrence

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser